144 related articles for article (PubMed ID: 2059756)
1. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.
Deeg HJ; Spitzer TR; Cottler-Fox M; Cahill R; Pickle LW
Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
[TBL] [Abstract][Full Text] [Related]
3. Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipients.
Aschan J; Ringdén O; Andström E; Ljungman P; Lönnqvist B; Remberger M
Bone Marrow Transplant; 1994 Jul; 14(1):79-87. PubMed ID: 7951124
[TBL] [Abstract][Full Text] [Related]
4. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
5. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
6. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.
Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Marusić M; Francetić I; Kastelan A
Bone Marrow Transplant; 1990 Aug; 6(2):137-41. PubMed ID: 2207450
[TBL] [Abstract][Full Text] [Related]
7. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
Atkinson K; Downs K
Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
[TBL] [Abstract][Full Text] [Related]
8. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Bertz H; Potthoff K; Mertelsmann R; Finke J
Bone Marrow Transplant; 1997 Jun; 19(12):1169-73. PubMed ID: 9208109
[TBL] [Abstract][Full Text] [Related]
9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
12. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
13. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
14. Marrow transplant experience for children with severe aplastic anemia.
Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
18. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience.
Hernández-Boluda JC; Marín P; Carreras E; Aguilar JL; Grañena A; Rozman C; Montserrat E
Haematologica; 1999 Jan; 84(1):26-31. PubMed ID: 10091390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]